TBPH icon

Theravance Biopharma

94 hedge funds and large institutions have $1.84B invested in Theravance Biopharma in 2017 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 37 increasing their positions, 26 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

more repeat investments, than reductions

Existing positions increased: | Existing positions reduced:

more first-time investments, than exits

New positions opened: | Existing positions closed:

more capital invested

Capital invested by funds: $ → $

more funds holding

Funds holding:

1.41% more ownership

Funds ownership: 85.37%86.78% (+1.4%)

0% more funds holding in top 10

Funds holding in top 10: 55 (0)

47% less call options, than puts

Call options by funds: $1.06M | Put options by funds: $1.99M

Holders
94
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
5
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
$1.06M
Puts
$1.99M
Net Calls
Net Calls Change

Top Buyers

1 +$39.9M
2 +$38.1M
3 +$6.48M
4
BlackRock
BlackRock
New York
+$5.04M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$4.66M

Top Sellers

1 -$18.9M
2 -$14.8M
3 -$7.23M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$3.34M
5
First Manhattan
First Manhattan
New York
-$3.24M
Name Holding Trade Value Shares
Change
Change in
Stake
51
$1.1M
52
$1.03M
53
$1.01M
54
$974K
55
$941K
56
$861K
57
$855K
58
$830K
59
$755K
60
$742K
61
$700K
62
$649K
63
$575K
64
$571K
65
$567K
66
$558K
67
$495K
68
$470K
69
$467K
70
$390K
71
$378K
72
$275K
73
$260K
74
$236K
75
$214K